

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS

05 AUG 17 PM 2:36

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name The OB-C Group, LLC			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1350 Eye Street, NW Suite 690 City Washington State/Zip (or Country) DC 20005 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name: Celeste Dembowski		Telephone 202-898-4746	E-mail (optional) cdembowski@ob-cgroup.com
			5. Senate ID # 29802-366
7. Client Name <input type="checkbox"/> Self Biotechnology Industry Organization			6. House ID # 30108032

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) ☒ OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____ 11. No Lobby

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >>\$ <u>\$160,000.00</u> Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	13. Organizations EXPENSES relating to lobbying activities for this rep period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >>\$ _____ Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of <input type="checkbox"/> Method A. Reporting amounts using LDA definit <input type="checkbox"/> Method B. Reporting amounts under section 603 the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code
--	---

Signature _____

Date 8/10/2005

0000410202



Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ACC (one per page)

16. Specific Lobbying issues

******, no specific bill number this term, incentive stock options and employee stock purchase plans.
H.R.913, Broad-Based Stock Option Plan Transparency Act, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005

0000410203

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

0000019204

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues

***, no specific bill, proposed policy re: adventitious presence.

H.R.2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Agriculture
Environmental Protection Agency
Food & Drug Administration
House of Representatives
Office of U.S. Trade Representative
Senate
The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005

3000410205



Printed Name and Title Celeste Dembowski - Office Administrator

P:

Registrant Name: **The OB-C Group, LLC**

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

000004102006

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

***, no specific bill number(s), supplemental appropriations budget(s).

H.R.2360, Department of Homeland Security Appropriations Act, 2006, entire bill.

H.R.2361, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2006, entire

H.R.2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006, entire bill.

H.R.2862, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2006, entire bill.

H.R.2863, Department of Defense Appropriations Act, 2006, entire bill.

H.R.3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Rublen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005



Client Name: Biotechnology Industry Organization

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

***, no specific bill, human cloning patent amendment.

H.R.2791, United States Patent and Trademark Fee Modernization Act of 2005, PTO fee reform.

H.R.2795, Patent Act of 2005, patent reform.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005

0000410209

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

1941-1942

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code DEF (one per page)

16. Specific Lobbying issues

***, no specific bill, biobased purchasing policy.

**, no specific bill, biothreat countermeasures.

S.3, Protecting America in the War on Terror Act of 2005, entire bill.

S.975, Project BioShield II Act of 2005, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005

0000410211

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

0000410212

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOO (one per page)

16. Specific Lobbying issues

H.R.1563, National Food and Agricultural Science Act of 2005, entire bill.

H.R.753, Safe IMPORT Act of 2005

Safe Importation of Medical Products and Other Rx Therapies Act of 2005, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

0000410214

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues

####, no specific bill, PDUFA implementation.

###, no specific bill, pharmacoeconomics.

##, no specific bill, gene, cell and tissue therapy.

****, no specific bill, FDA drug safety.

****, no specific bill, FDA review practices.

***, no specific bill, NIH conflict of interest.

** , no specific bill, Bayh-Dole March-in rights.

*, no specific bill, clinical trial information disclosure.

H.R.1650, Stem Cell Research Investment Act of 2005, entire bill.

H.R.2520, Stem Cell Therapeutic and Research Act of 2005, entire bill.

H.R.596, Cord Blood Stem Cell Act of 2005, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005

0000410215



Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

Item	Description	Data
16	Lobbying Issues	H.R.810, Stem Cell Research Enhancement Act of 2005, entire bill.
16	Lobbying Issues	S.317, Library, Bookseller, and Personal Records Privacy Act, entire bill.
16	Lobbying Issues	S.471, Stem Cell Research Enhancement Act of 2005, entire bill.
16	Lobbying Issues	S.681, Cord Blood Stem Cell Act of 2005, entire bill.
16	Lobbying Issues	S.876, Human Cloning Ban and Stem Cell Research Protection Act of 2005, en bill.

18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

0000410216

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

###, no specific bill, Medicaid.

****, no specific bill, reconciliation.

***, no specific bill, MMA implementation.

+++, no specific bill, off-label studies.

H.R.1626, Medicare Prescription Drug Improvement Act, entire bill.

H.R.563, Prescription Drug Affordability Act of 2005, entire bill.

H.R.752, Medicare Prescription Drug Savings and Choice Act of 2005, entire bill.

S.873, Medicare Prescription Drug Savings and Choice Act of 2005, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

8
7
6
5
4
3
2
1

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005, entire bill.

S.334, Pharmaceutical Market Access and Drug Safety Act of 2005, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

House of Representatives

Senate

White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/2005

0000410219



Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

0000410220

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SMB (one per page)

16. Specific Lobbying issues

H.R.2943, SABIR Act - Save Biotechnology Innovative Research Act of 2005, section 382 issues.

S.1263, SABIR Act - Save America's Biotechnology Innovative Research Act of 2005, section 382 issues.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Peleske Embrose

Date 8/10/2005



Registrant Name: **The OB-C Group, LLC**

Client Name: Biotechnology Industry Organization

00000000

